2022 World Conference on Lung Cancer (ePosters)-EP08.02-131. Alectinib after Crizotinib Failure in Patients with Advanced ALK-Positive NSCLC: Results from the Spanish Early Access Program

EP08.02-131. Alectinib after Crizotinib Failure in Patients with Advanced ALK-Positive NSCLC: Results from the Spanish Early Access Program

Back to course

Pdf Summary

This study focuses on the use of alectinib, a new generation anaplastic lymphoma kinase (ALK)-tyrosine kinase inhibitor (TKI), in patients with advanced ALK-positive non-small cell lung cancer (NSCLC) who had previously failed treatment with crizotinib. The study analyzed the data of 120 patients who participated in an expanded access program (EAP) in Spain between November 2019 and November 2020. The aim was to describe the patient population and report on the effectiveness and safety of alectinib in this heavily pre-treated population.<br /><br />The results showed that alectinib had a favorable safety profile, with the most common adverse events being increased transaminase levels, dyspnea, and asthenia. The mean duration of treatment with alectinib was 13.9 months, and the median duration of response was 10.2 months. The objective response rate was 54.5%, and the disease control rate was 80%. Patients with central nervous system (CNS) metastases also showed positive responses to alectinib, with an intracranial objective response rate of 28.6% and a disease control rate of 71.4%.<br /><br />The study concluded that alectinib demonstrated effectiveness and tolerability in heavily pre-treated patients with advanced ALK-positive NSCLC. The findings confirm the benefits of alectinib observed in clinical trials and highlight its potential in real-world clinical practice. The study also revealed the common sites of metastases in ALK-positive NSCLC, with lung and bone being the most affected. Management of CNS metastases often involved local treatments such as whole-brain radiotherapy and radiosurgery.<br /><br />The study was funded by Roche Farma S.A., the manufacturer of alectinib. Overall, the study adds to the growing body of evidence supporting the use of alectinib as a treatment option for advanced ALK-positive NSCLC patients who have failed prior therapy.

Asset Subtitle

Reyes Bernabé-Caro

Meta Tag

Speaker Reyes Bernabé-Caro

Topic Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments

Keywords

alectinib

ALK-positive non-small cell lung cancer

tyrosine kinase inhibitor

crizotinib

expanded access program

effectiveness

safety

adverse events

metastases

clinical trials